Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation
CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell lymphoma who haven’t experienced improvement with chemotherapy treatments. But if this CAR-T treatment fails, or the cancer returns yet again — as happens in approximately half of … Read more
